Author(s):
Mayur S. Mahajan, K. R. Bobe, B. B. Chavan
Email(s):
mayurmahajn862000@gmail.com
DOI:
10.52711/0975-4377.2023.00020 
Address:
Mayur S. Mahajan*, K. R. Bobe, B. B. Chavan
Department of Pharmaceutics, JSPM's Jayawantrao Sawant College of Pharmacy and Research, Pune, 411028, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2023
ABSTRACT:
Coronavirus disease 2019 (COVID-19) is a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that belongs to the coronavirus family. The first case was reported in December 2019, and the disease has become a pandemic. Impaired immune regulation is one of the factors that play a role in its pathogenesis and results in poor outcomes of COVID-19 patients. There have been many studies with drug candidates used as antivirals or immunomodulators. However, the results of these investigations showed that the drug candidates were not significantly effective against the disease. Meanwhile, people believe that consuming herbal immunomodulators can prevent or even cure COVID-19. Unfortunately, specific preclinical and clinical trials to evaluate the effects of herbal immunoregulators have not been conducted. Certain natural compounds might be effective for the treatment of COVID-19 based on general concepts from previous experiments. This review discusses some herbal agents extracted from various plants, including Curcuma longa, Cinchona, Ashwagandh aand Lianhuaqingwen, which are considered for the treatment of COVID-19. In addition, we discuss the pros and cons of utilising herbal medicine during the COVID-19 pandemic, draw some conclusions, and make recommendations at the end of the session.
Cite this article:
Mayur S. Mahajan, K. R. Bobe, B. B. Chavan. Traditional Ayurvedic Formulation in the Management of COVID-19. Research Journal of Pharmaceutical Dosage Forms and Technology.2023; 15(2):115-2. doi: 10.52711/0975-4377.2023.00020
Cite(Electronic):
Mayur S. Mahajan, K. R. Bobe, B. B. Chavan. Traditional Ayurvedic Formulation in the Management of COVID-19. Research Journal of Pharmaceutical Dosage Forms and Technology.2023; 15(2):115-2. doi: 10.52711/0975-4377.2023.00020 Available on: https://rjpdft.com/AbstractView.aspx?PID=2023-15-2-8
REFERENCE:
1. Cucinotta, Domenico, and Maurizio Vanelli. "WHO declares COVID-19 a pandemic." Acta Bio Medica: Atenei Parmensis 91.1 (2020): 157.
2. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Schuchat A, Ungchusak K. COVID-19: towards controlling of a pandemic. The lancet. 2020 Mar 28;395(10229):1015-8.
3. World Health Organization (WHO) Report: https://covid19.who.int/
4. B. V. Naresh. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3):233-238.
5. Chojnacka K, Witek-Krowiak A, Skrzypczak D, Mikula K, Młynarz P. Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus. Journal of Functional Foods. 2020 Jul 30:104146.
6. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. International journal of biological sciences. 2020;16(10):1708.
7. Z. Y. Zu, M. Di Jiang, P. P. Xu et al., “Coronavirus disease 2019 (COVID-19): a perspective from China,” Radiology, vol. 296, no. 2, pp. 1–29, 2020.
8. S.-Q. Deng and H.-J. Peng, “Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China,” Journal of Clinical Medicine, vol. 9, no. 575, pp. 1–10, 2020.
9. A. R. Fehr and S. Perlman, “Coronaviruses: an overview of their replication and pathogenesis,” Coronaviruses, vol. 1282, pp. 1–23, 2015.
10. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020 Feb 22;395(10224):565-74.
11. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections. 2020 Jan 1;9(1):221-36.
12. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar;579(7798):270-3.
13. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology. 2020 Mar 17;94(7).
14. Rahate Snehal Kishor, Bombale Mayur Ramhari. Introduction to Covid-19. Research J. Science and Tech. 2020; 12(4):338-345.
15. Sheila Menon FBSCH, Vidya Bhagat. Review of the impact Covid-19 has on the Psychosocial factors affecting Well-Being. Research Journal of Pharmacy and Technology. 2021; 14(6):3404-8.
16. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020 May 1;10(5):766-88.
17. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020 Apr 16;181(2):271-80.
18. Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 immunopathology and immunotherapy. Bioinformation. 2020;16(3):219.
19. Sarfaraz Ahmad, Ambreen Shoaib, Sajid Ali, Sarfaraz Alam, Nawazish Alam, Maksood Ali, Ali Mujtaba, Ayaz Ahmad, Salahuddin Ansari, Mohammad Daud Ali. Epidemiology, risk, myths, pharmacotherapeutic management and socio economic burden due to novel COVID-19: A recent update. Research J. Pharm. and Tech 2020; 13(9):4435-4442.
20. Vandna Dewangan, Ram Sahu, Trilochan Satapathy, Amit Roy. The Exploring of Current Development status and the unusual Symptoms of Coronavirus Pandemic (Covid-19). Res. J. Pharmacology and Pharmacodynamics.2020; 12(4):172-176.
21. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology. 2020 Mar 17;94(7).
22. Rohit Kumar, Anshul Chawla, Gaganpreet, Diksha. A Valuable insight to the novel deadly COVID-19: A Review. Res. J. Pharmacology and Pharmacodynamics.2020; 12(3):111-116.
23. Paresh A. Patil, Ritik. S. Jain. Theoretical Study and treatment of Novel COVID-19. Res. J. Pharmacology and Pharmacodynamics.2020; 12(2): 71-72.
24. Rahate Snehal Kishor, Bokand Mayur Rajendra, Bombale Mayur Ramhari, Suhas Shivaji Siddheshwar. Review Paper on Ayush System of Medicine against COVID-19. ch Journal of Pharmacognosy and Phytochemistry. 2021; 13(2):103-6.
25. Sonali S Gadge. Antiviral and Immunity-modulating Natural Herbs in the Prevention of COVID-19. Research Journal of Pharmacognosy and Phytochemistry. 2021; 13(2):81-4.
26. Samir Derouiche. Current Review on Herbal Pharmaceutical improve immune responses against COVID-19 infection. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):181-184.
27. Ajay I. Patel, Pooja R. Maru, Ashok B. Patel, Amitkumar J. Vyas, Nilesh K. Patel. Role of Vitamins, Minerals and Herbs in Strengthening immune system against the newly Emerging Viral Disease SARS-CoV-2. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(4):309-5.
28. Manoharan Y, Haridas V, Vasanthakumar KC, Muthu S, Thavoorullah FF, Shetty P. Curcumin: A wonder drug as a preventive measure for COVID19 management. Indian Journal of Clinical Biochemistry. 2020 Jul;35(3):373-5.
29. Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik N. Traditional herbal medicine candidates as complementary treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. Evidence-Based Complementary and Alternative Medicine. 2020 Oct 10;2020.
30. Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, Tripathi YB. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants–Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi)–a molecular docking study. Journal of Biomolecular Structure and Dynamics. 2020 Aug 26:1-4.
31. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological research. 2020 Jun 1;156:104761.
32. Pang XF, Zhang LH, Bai F, Wang NP, Garner RE, McKallip RJ, Zhao ZQ. Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug design, development and therapy. 2015;9:6043.
33. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine. 2020 Apr;46(4):586-90.
34. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1–7). Cardiovascular research. 2007 Feb 1;73(3):463-9.
35. Li HY, Yang M, Li Z, Meng Z. Curcumin inhibits angiotensin II-induced inflammation and proliferation of rat vascular smooth muscle cells by elevating PPAR-γ activity and reducing oxidative stress. International Journal of Molecular Medicine. 2017 May 1;39(5):1307-16.
36. Maldonado C, Barnes CJ, Cornett C, Holmfred E, Hansen SH, Persson C, Antonelli A, Rønsted N. Phylogeny predicts the quantity of antimalarial alkaloids within the iconic yellow Cinchona bark (Rubiaceae: Cinchona calisaya). Frontiers in Plant Science. 2017 Mar 22;8:391.
37. S. D’alessandro, D. Scaccabarozzi, L. Signorini et al., “The use of antimalarial drugs against viral infection,” Microorganisms, vol. 8, no. 85, pp. 1–26, 2020.
38. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005 Dec;2(1):1-0.
39. Seeler AO, Graessle O, Ott WH. Effect of quinine on influenza virus infections in mice. The Journal of infectious diseases. 1946 Sep 1:156-8.
40. Baroni A, Paoletti I, Ruocco E, Ayala F, Corrado F, Wolf R, Tufano MA, Donnarumma G. Antiviral effects of quinine sulfate on HSV-1 HaCat cells infected: analysis of the molecular mechanisms involved. Journal of dermatological science. 2007 Sep 1;47(3):253-5.
41. Owen JA, Punt J, Stanford SA. Innate Immunity. InKUBY Immunology.
42. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nature reviews immunology. 2008 Jul;8(7):559-68.
43. Malakar S, Sreelatha L, Dechtawewat T, Noisakran S, Yenchitsomanus PT, Chu JJ, Limjindaporn T. Drug repurposing of quinine as antiviral against dengue virus infection. Virus research. 2018 Aug 15;255:171-8.
44. Maruyama N, Kakuta Y, Yamauchi K, Ohkawara Y, Aizawa T, Ohrui T, Nara M, Oshiro T, Ohno I, Tamura G. Quinine inhibits production of tumor necrosis factor-alpha from human alveolar macrophages. American journal of respiratory cell and molecular biology. 1994 May;10(5):514-20.
45. Ittarat W, Udomsangpetch R, Chotivanich KT, Looareesuwan S. The effects of quinine and artesunate treatment on plasma tumor necrosis factor levels in malaria-infected patients. The Southeast Asian journal of tropical medicine and public health. 1999 Mar 1;30(1):7-10.
46. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrobial agents and chemotherapy. 2009 Aug 1;53(8):3416-21.
47. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020.
48. Zhonghua J, He H, Hu X, Za Z. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Biblioteca Nacional de medicina. 2020 Mar 12;43:185-8.
49. Srivastava AK, Chaurasia JP, Khan R, Dhand C, Verma S. Role of Medicinal plants of Traditional Use in Recuperating Devastating COVID-19 Situation. Med Aromat Plants (Los Angeles). 2020;9(359):2167-0412.
50. Singh RH, Narsimhamurthy K, Singh G. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology. 2008 Dec;9(6):369-74.
51. Williamson EM. Major herbs of Ayurveda. Churchill Livingstone; 2002.
52. Ven Murthy MR, K Ranjekar P, Ramassamy C, Deshpande M. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: 1. Ashwagandha. Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents). 2010 Sep 1;10(3):238-46.
53. Vyas VK, Pratik B, Radheshyam P. A comprehensive review on Withania somnifera Dunal. Journal of Natural Remedies. 2011;11(1):1-3.
54. Kapoor LD. Handbook of Ayurvedic medicinal plants: Herbal reference library. CRC press; 2000 Nov 10.
55. Matsuda H, Murakami T, Kishi A, Yoshikawa M. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Bioorganic & medicinal chemistry. 2001 Jun 1;9(6):1499-507.
56. Maurya DK, Sharma D. Evaluation of traditional ayurvedic preparation for prevention and management of the novel coronavirus (SARS-CoV-2) using molecular docking approach.
57. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q. leng Cheng P, Yutao W, Zheng J, Yang Z, Zhang F. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC complementary and alternative medicine. 2017 Dec;17(1):130.
58. Duan ZP, Jia ZH, Zhang J, Shuang L, Yu C, Liang LC, Zhang CQ, Zhang Z, Yan SU, Zhang SQ, Wang YY. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chinese medical journal. 2011 Sep 2;124(18):2925-33.
59. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends. 2020 Feb 29;14(1):69-71.
60. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological research. 2020 Jun 1;156:104761.
61. Yanjiao M, Zhongyi Z, Lianbo W, Shuai H, Xun D, Aimin J, Benjie Z, Deqi J, Mingxing L, Yong W. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. Journal of Traditional Chinese Medicine. 2017 Apr 1;37(2):185-92.
62. Zhao P, Yang HZ, Lv HY, Wei ZM. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Altern Ther Health Med. 2014 Mar 1;20(2):25-30.
63. Wang CH, Zhong Y, Zhang Y, Liu JP, Wang YF, Jia WN, Wang GC, Li Z, Zhu Y, Gao XM. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. Molecular BioSystems. 2016;12(2):606-13.
64. Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 2020 May 16:153242.